LLG 783

Drug Profile

LLG 783

Alternative Names: LLG783

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action LDL receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intermittent claudication; Peripheral arterial disorders

Most Recent Events

  • 20 Sep 2017 Phase-II clinical trials in Intermittent claudication in USA (IV) (NCT03194776)
  • 20 Sep 2017 Phase-II clinical trials in Peripheral arterial disorders in USA (IV) (NCT03194776)
  • 19 Jun 2017 Novartis Pharmaceuticals plans a phase II trial for Peripheral arterial disorders (In adults, In the elderly, Treatment-experienced) and Intermittent claudication (In adults, In the elderly, Treatment-experienced) (IV) (NCT03194776)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top